Skip to main content

Herbert B. Newton, MD, FAAN

Herbert B. Newton, MD, FAAN

Medical Director (Neuro Onc), Psychiatrist, Neuro-Oncologist

Cancer

Herbert Newton

Overview

Herbert Bruce Newton, MD, FAAN is a board-certified neuro-oncologist and neurologist who joins the Neuro-Oncology Center after more than 30 years of highly specialized experience in the fields of neuro-oncology and neurology. His primary focus is diagnosis, treatment, and skilled medical care of adult and adolescent patients with tumors of the brain or spinal cord, and complications of brain tumors, specifically epilepsy. Dr. Newton specializes in the use of chemotherapy and molecular therapeutics. Dr. Newton is highly acclaimed in the field, with more than 200 publications in scientific journals and 7 medical textbooks. He has been recognized by Newsweek as one of America’s Top Doctors for Cancer (2005-2015) and is a former Chair of the American Academy of Neurology Section of Neuro-Oncology.

Articles

Successful Intrathecal Rituximab Administration in Refractory Nonteratoma Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report

JOURNAL OF NEUROSCIENCE NURSING

2019

Oligodendrogliomas-Atypical clinical presentations

OLIGODENDROGLIOMA: CLINICAL PRESENTATION, PATHOLOGY, MOLECULAR BIOLOGY, IMAGING, AND TREATMENT

2019

Temozolomide chemotherapy for oligodendroglial tumors

OLIGODENDROGLIOMA: CLINICAL PRESENTATION, PATHOLOGY, MOLECULAR BIOLOGY, IMAGING, AND TREATMENT

2019

Miscellaneous chemotherapy approaches to oligodendroglial tumors

OLIGODENDROGLIOMA: CLINICAL PRESENTATION, PATHOLOGY, MOLECULAR BIOLOGY, IMAGING, AND TREATMENT

2019

Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis

JOURNAL OF NEURO-ONCOLOGY

2015

Education & Training

Education

SUNY Buffalo Medical School, Buffalo, NY

Residency

University of Michigan Medical Center, Ann Arbor, MI

Fellowship

Memorial Sloan-Kettering Cancer Center, New York, NY

Specialty

Neuro Oncology

Board Certifications

American board of Psychiatry and Neurology

Associated Clinical Trials

NCT03377491

PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

Icon for trial | EF-27 PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

This study is currently enrolling.

The purpose of this study is to evaluate the efficacy and safety of TTFields together with standard chemotherapy (gemcitabine and nab-paclitaxel) compared to standard chemotherapy (gemcitabine and nab-paclitaxel) without TTFiel ...

NCT03856099

A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

Icon for trial | PMC_TTAC-0001_03 A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy

This study is currently enrolling.

The aim of this study is to assess the safety and effectiveness of the study drug, TTAC-0001 to patients with recurrent glioblastoma which has progressed on bevacizumab treatment. Another aim is to measure the levels of TTAC-00 ...

NCT0887146

Phase III Integraoup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Icon for trial | N0577 Phase III Integraoup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

This study is currently enrolling.

The purpose of this study is to compare the effectiveness of either 1) radiotherapy (RT, radiation therapy) along with temozolomide chemotherapy followed by additional temozolomide chemotherapy (RT + TMZ -> TMZ); or 2) radio ...